Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Efdamrofusp Alfa (IBI302) in Neovascular Age-related Macular Degeneration
NCT04820452Phase 2Completed
- Sponsor
- Innovent Biologics
- Start
- Apr 2021
- Primary completion
- Jan 2023
- Modality
- Bispecific Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of efdamrofusp alfa in neovascular age-related macular degeneration (NVAMD), sponsored by Innovent Biologics. Started Apr 2021; status: completed.
02
Drugs
efdamrofusp alfa
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04820452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04820452.